- Home
- PAYO vs MIRM Comparison
PAYO vs MIRM Comparison
Compare PAYO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- MIRM
- Stock Information
- Founded
- PAYO 2005
- MIRM 2018
- Country
- PAYO United States
- MIRM United States
- Employees
- PAYO N/A
- MIRM N/A
- Industry
- PAYO EDP Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- MIRM Health Care
- Exchange
- PAYO Nasdaq
- MIRM Nasdaq
- Market Cap
- PAYO 2.5B
- MIRM 2.5B
- IPO Year
- PAYO N/A
- MIRM 2019
- Fundamental
- Price
- PAYO $6.99
- MIRM $49.51
- Analyst Decision
- PAYO Strong Buy
- MIRM Strong Buy
- Analyst Count
- PAYO 8
- MIRM 9
- Target Price
- PAYO $10.44
- MIRM $66.22
- AVG Volume (30 Days)
- PAYO 2.6M
- MIRM 449.1K
- Earning Date
- PAYO 08-06-2025
- MIRM 08-06-2025
- Dividend Yield
- PAYO N/A
- MIRM N/A
- EPS Growth
- PAYO N/A
- MIRM N/A
- EPS
- PAYO 0.28
- MIRM N/A
- Revenue
- PAYO $996,150,000.00
- MIRM $379,251,000.00
- Revenue This Year
- PAYO $4.32
- MIRM $35.83
- Revenue Next Year
- PAYO $5.59
- MIRM $16.83
- P/E Ratio
- PAYO $24.75
- MIRM N/A
- Revenue Growth
- PAYO 14.86
- MIRM 69.31
- 52 Week Low
- PAYO $5.03
- MIRM $33.45
- 52 Week High
- PAYO $11.29
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- PAYO 53.72
- MIRM 55.85
- Support Level
- PAYO $6.61
- MIRM $47.89
- Resistance Level
- PAYO $6.95
- MIRM $51.93
- Average True Range (ATR)
- PAYO 0.19
- MIRM 1.44
- MACD
- PAYO 0.03
- MIRM -0.30
- Stochastic Oscillator
- PAYO 87.93
- MIRM 39.98
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.